Barclays Maintains Overweight on Humana, Raises Price Target to $582

Barclays analyst Andrew Mok has maintained an Overweight rating on Humana (NYSE: HUM) and increased the price target from $515 to $582. This adjustment reflects a positive outlook on the company's performance.